Filing Flows › Exagen (XGN) › Q2 2026 › vs Q2 2025
Exagen (XGN) Q2 2026 vs Q2 2025 (year over year)
Exagen's revenue rose $2.7M (+16%) from $17.2M in Q2 2025 to $19.9M in Q2 2026.
Exagen, Q2 2026: revenue $19.9M (+16% year over year), operating margin -8.6%, net loss $3.2M, operating cash flow $4.0M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 17.3% | -18.0% | +35.3 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $19.9M | $17.2M | $2.7M | +16% |
| Net loss | $3.2M | $4.4M | −$1.2M | -28% |
| Costs & expenses | $23.1M | $21.6M | $1.5M | +7% |
| Operating costs | $21.7M | $19.8M | $1.8M | +9% |
| Interest & other, net | $1.5M | $1.8M | −$298K | -17% |
| Cost of revenue | $7.7M | $6.8M | $917K | +13% |
| Research & development | $1.4M | $1.5M | −$57K | -4% |
| SG&A | $12.5M | $11.5M | $971K | +8% |
| Operating cash sources | $7.2M | $1.6M | $5.6M | +362% |
| Depreciation & amortization | $600K | $500K | $100K | +20% |
| Share-based compensation | $980K | $443K | $537K | +121% |
| Working capital & other | $5.6M | $611K | $5.0M | +817% |
| Net loss absorbed | $3.2M | $4.4M | −$1.2M | -28% |
| Operating cash flow | $4.0M | −$2.9M | $6.9M | — |
| Free cash flow (OCF − capex) | $3.4M | −$3.1M | $6.5M | — |
| Capital expenditures | $543K | $209K | $334K | +160% |
Questions
How much did Exagen's revenue grow year over year in Q2 2026?
Exagen's revenue rose $2.7M (+16%) from $17.2M in Q2 2025 to $19.9M in Q2 2026.